Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?
作者信息
Vigorito Afonso Celso
机构信息
Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil.
出版信息
Rev Bras Hematol Hemoter. 2016 Oct-Dec;38(4):281-282. doi: 10.1016/j.bjhh.2016.07.006. Epub 2016 Sep 9.
Abstract
摘要
相似文献
1
Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?对于先前接受过环磷酰胺、沙利度胺和地塞米松治疗的多发性骨髓瘤患者进行自体移植时的造血干细胞动员：仅使用粒细胞集落刺激因子是否足够？
Rev Bras Hematol Hemoter. 2016 Oct-Dec;38(4):281-282. doi: 10.1016/j.bjhh.2016.07.006. Epub 2016 Sep 9.
2
Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?单独使用粒细胞集落刺激因子来动员接受环磷酰胺、沙利度胺和地塞米松方案诱导的多发性骨髓瘤患者的祖细胞是否可行？
Rev Bras Hematol Hemoter. 2016 Oct-Dec;38(4):302-309. doi: 10.1016/j.bjhh.2016.06.004. Epub 2016 Jul 29.
3
Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.环磷酰胺联合粒细胞集落刺激因子用于多发性骨髓瘤患者造血干细胞动员
J Clin Apher. 2016 Oct;31(5):423-8. doi: 10.1002/jca.21421. Epub 2015 Sep 5.
4
Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.粒细胞集落刺激因子与粒细胞巨噬细胞集落刺激因子联合强化化疗用于多发性骨髓瘤外周血干细胞动员和自体移植的随机对照研究
Biol Blood Marrow Transplant. 2004 Jun;10(6):395-404. doi: 10.1016/j.bbmt.2004.02.001.
5
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.沙利度胺、环磷酰胺和地塞米松诱导疗法：适用于准备进行自体干细胞移植的骨髓瘤患者的可行性。
Acta Haematol. 2014;132(2):226-32. doi: 10.1159/000357659.
6
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.新型诱导疗法治疗多发性骨髓瘤患者的外周血造血干细胞动员：中剂量与低剂量环磷酰胺和粒细胞集落刺激因子。
Biol Blood Marrow Transplant. 2012 Jul;18(7):1128-35. doi: 10.1016/j.bbmt.2012.01.005. Epub 2012 Jan 14.
7
Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.基于诱导治疗反应的多发性骨髓瘤动员方案选择：单纯粒细胞集落刺激因子（G-CSF）与大剂量环磷酰胺加G-CSF对比
Leuk Lymphoma. 2016;57(6):1389-97. doi: 10.3109/10428194.2015.1102240. Epub 2015 Nov 16.
8
Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.在接受包含硼替佐米、环磷酰胺和地塞米松的统一诱导方案治疗的多发性骨髓瘤患者中，不同干细胞动员方式后的植入情况比较。
Ann Hematol. 2017 Mar;96(3):461-467. doi: 10.1007/s00277-016-2897-2. Epub 2016 Dec 24.
9
Granulocyte colony-stimulating factor utilization postautologous hematopoietic stem cell transplant in multiple myeloma patients: Does one size fit all?多发性骨髓瘤患者自体造血干细胞移植后粒细胞集落刺激因子的应用：一种方案适用于所有人吗？
J Oncol Pharm Pract. 2019 Jul;25(5):1135-1141. doi: 10.1177/1078155218781888. Epub 2018 Jun 11.
10
Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.超越 CD34+ 细胞剂量：外周血造血干细胞动员方法（粒细胞集落刺激因子[G-CSF]、G-CSF 加plerixafor 或环磷酰胺 G-CSF/粒细胞-巨噬细胞[GM]-CSF）对集落形成单位-GM 数量、植入和第 100 天造血移植物功能的影响。
Transfusion. 2011 Sep;51(9):1995-2000. doi: 10.1111/j.1537-2995.2011.03085.x. Epub 2011 Mar 10.
引用本文的文献
1
The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience.多发性骨髓瘤诱导治疗对造血干细胞动员和采集的影响：25年经验
Hematol Transfus Cell Ther. 2019 Oct-Dec;41(4):285-291. doi: 10.1016/j.htct.2019.03.005. Epub 2019 Jun 14.
本文引用的文献
1
Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?单独使用粒细胞集落刺激因子来动员接受环磷酰胺、沙利度胺和地塞米松方案诱导的多发性骨髓瘤患者的祖细胞是否可行？
Rev Bras Hematol Hemoter. 2016 Oct-Dec;38(4):302-309. doi: 10.1016/j.bjhh.2016.06.004. Epub 2016 Jul 29.
2
Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.多发性骨髓瘤的造血干细胞移植：美国血液和骨髓移植学会指南
Biol Blood Marrow Transplant. 2015 Jul;21(7):1155-66. doi: 10.1016/j.bbmt.2015.03.002. Epub 2015 Mar 11.
3
Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy.在新型药物治疗时代，利用储存的自体外周血干细胞支持多发性骨髓瘤患者进行第二次自体移植。
Bone Marrow Transplant. 2015 May;50(5):663-7. doi: 10.1038/bmt.2015.13. Epub 2015 Mar 2.
4
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.多发性骨髓瘤患者的生存率持续提高：老年患者早期死亡率和结局的变化。
Leukemia. 2014 May;28(5):1122-8. doi: 10.1038/leu.2013.313. Epub 2013 Oct 25.
5
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).国际骨髓瘤工作组（IMWG）关于多发性骨髓瘤干细胞采集及大剂量治疗现状以及普乐沙福（AMD 3100）作用的共识声明与指南
Leukemia. 2009 Oct;23(10):1904-12. doi: 10.1038/leu.2009.127. Epub 2009 Jun 25.
6
Improving stem cell mobilization strategies: future directions.改善干细胞动员策略：未来方向。
Bone Marrow Transplant. 2009 Feb;43(3):181-95. doi: 10.1038/bmt.2008.410. Epub 2009 Jan 12.
7
Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.大剂量环磷酰胺与生长因子联合应用和单独使用生长因子对多发性骨髓瘤患者进行干细胞动员以用于移植的比较。
Bone Marrow Transplant. 2009 Apr;43(8):619-25. doi: 10.1038/bmt.2008.369. Epub 2008 Nov 10.
Zotero 插件